Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

AB154 and AB122 Before Surgery for the Treatment of Recurrent Glioblastoma

Trial Status: closed to accrual and intervention

This phase I trial evaluates the side effects of AB154 and AB122 in treating patients with glioblastoma that has come back (recurrent). Immunotherapies like AB154 and AB122 try to use a patient’s own immune system to fight cancer. AB154 and AB122 are antibodies that target proteins thought to help tumor cells to hide from the immune system. Giving AB154 and AB122 may slow or stop the growth of cancer cells in patients with glioblastoma.